Department of Medical Oncology, Catalan Institute of Oncology - ICO, L'Hospitalet de Llobregat, Barcelona, Spain.
Breast Cancer Group, Institut d'Investigacio Biomedica de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Breast Cancer Res Treat. 2022 Jun;193(2):281-291. doi: 10.1007/s10549-022-06575-7. Epub 2022 Apr 9.
A deeper insight into tumor biology and HER2 signaling has led to the development of novel anti-HER2 drugs that have significantly improved the prognosis of patients with HER2-positive breast cancer. The breast cancer immune microenvironment has emerged as a potential prognostic factor. Moreover, the host immune system not only seems to play a critical role in the prognosis of HER2-positive breast cancer, but also seems to modulate treatment response to some HER2-targeted agents. Here, we review the latest evidence of the role of immunotherapy in HER2-positive breast cancer and present emerging strategies.
对肿瘤生物学和 HER2 信号的更深入了解导致了新型抗 HER2 药物的开发，这些药物显著改善了 HER2 阳性乳腺癌患者的预后。乳腺癌免疫微环境已成为一个潜在的预后因素。此外，宿主免疫系统不仅似乎在 HER2 阳性乳腺癌的预后中发挥关键作用，而且似乎还调节了一些针对 HER2 的靶向药物的治疗反应。在这里，我们回顾了免疫疗法在 HER2 阳性乳腺癌中的作用的最新证据，并提出了新的策略。
